Tenaya Therapeutics Inc (TNYA) Stock Price, Quote & News

Company Profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone de...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 825 6990

Website: www.tenayatherapeutics.com

Address:

171 Oyster Point Boulevard, Suite 500, South San Francisco, United States

Paulfrench Oct. 11 at 8:55 AM

$TNYA The price crossed the 400MA without (too much) difficulty, the good news is that we closed above this line. Now a slight resistance zone has formed between $2.11 and $2.35, this is our next target. The price may be able to play around the 400MA for a few days or weeks, but I am convinced that the bullish movement is not over, because the real catalysts have not yet fallen (the results of the studies)... my advice is to hold on!

3 · Reply

kaizenj Oct. 10 at 9:52 PM

$TNYA this run up has legs, up and right to the American Heart Association conference in November for the interim data

0 · Reply

wins2love Oct. 10 at 9:30 PM

$TNYA Rough day in the market and we managed to stay positive. Forrest Gump shrimp boat level success. 😎

0 · Reply

JohnCardin Oct. 10 at 8:08 PM

$TNYA China proof!

0 · Reply

BadyBady Oct. 10 at 6:17 PM

$CUE $TNYA $IOBT Trump would make us rich—he’d escalate tensions with China, stocks would crash, and within a week at most, he’d reconcile and the market would bounce back. What happened during his presidency —those were golden opportunities. 😍

0 · Reply

DylanGFM Oct. 10 at 5:49 PM

$UAMY $CRML $TNYA $ONMD $DVLT best swing plays

0 · Reply

mansleeping373 Oct. 10 at 5:26 PM

$TNYA Lol. I slept through the pump this morning. Feeling pretty great overall, even after the pullback. Let's just end this day positive, PLEASE.

0 · Reply

popeyecallings Oct. 10 at 5:08 PM

$TNYA 😏

0 · Reply

wins2love Oct. 10 at 4:48 PM

$TNYA no expert here, but judging by the volume swings, it looks like a large player or group established position(s) in the open market beginning yesterday and concluding this AM. If that is correct, it will become apparent in the not too distant future.

0 · Reply

ezg43 Oct. 10 at 3:30 PM

$TNYA (love emoji) lFG

0 · Reply

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

Oct 2, 2025, 4:05 PM EDT - 9 days ago

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

Sep 18, 2025, 4:05 PM EDT - 23 days ago

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Sep 9, 2025, 11:07 PM EDT - 4 weeks ago

Tenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 4:05 PM EDT - 5 weeks ago

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 31, 2025, 10:15 AM EDT - 5 weeks ago

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

Aug 8, 2025, 8:00 AM EDT - 2 months ago

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 2 months ago

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 8:30 AM EDT - 2 months ago

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

May 13, 2025, 8:30 AM EDT - 5 months ago

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

Apr 24, 2025, 2:07 PM EDT - 6 months ago

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Mar 31, 2025, 10:00 AM EDT - 6 months ago

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Mar 24, 2025, 8:30 AM EDT - 7 months ago

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Mar 19, 2025, 8:30 AM EDT - 7 months ago

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Mar 10, 2025, 4:05 PM EDT - 7 months ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 11:19 PM EST - 7 months ago

Tenaya Therapeutics Announces Pricing of Public Offering

Mar 3, 2025, 4:10 PM EST - 7 months ago

Tenaya Therapeutics Announces Proposed Public Offering

Mar 3, 2025, 8:00 AM EST - 7 months ago

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Feb 3, 2025, 8:30 AM EST - 8 months ago

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Jan 13, 2025, 9:16 AM EST - 9 months ago

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Dec 16, 2024, 4:30 PM EST - 10 months ago

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

Jun 27, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics Announces Research Leadership Updates

Jun 18, 2024, 4:30 PM EDT - 1 year ago

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

May 14, 2024, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 5:00 PM EDT - 1 year ago

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

Feb 26, 2024, 8:30 AM EST - 1 year ago

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Feb 8, 2024, 8:00 AM EST - 1 year ago

Tenaya Therapeutics Announces Pricing of Underwritten Offering

Jan 3, 2024, 8:30 AM EST - 1 year ago

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:30 PM EST - 2 years ago

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

Oct 26, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

Oct 9, 2023, 8:30 AM EDT - 2 years ago

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

Oct 2, 2023, 5:30 PM EDT - 2 years ago

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Sep 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

Sep 21, 2023, 5:11 AM EDT - 2 years ago

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

SCLX SGHT TSBX

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 4:19 PM EDT - 2 years ago

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023, 7:50 AM EDT - 2 years ago

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

Apr 26, 2023, 7:00 AM EDT - 2 years ago

Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

NKTX

Apr 21, 2023, 4:05 PM EDT - 2 years ago

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 8, 2023, 4:01 PM EST - 2 years ago

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 7, 2023, 5:17 PM EST - 2 years ago

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

Dec 7, 2022, 4:30 PM EST - 3 years ago

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

Nov 28, 2022, 8:30 AM EST - 3 years ago

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

Nov 23, 2022, 9:00 AM EST - 3 years ago

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

Paulfrench Oct. 11 at 8:55 AM

3 · Reply

kaizenj Oct. 10 at 9:52 PM

$TNYA this run up has legs, up and right to the American Heart Association conference in November for the interim data

0 · Reply

wins2love Oct. 10 at 9:30 PM

$TNYA Rough day in the market and we managed to stay positive. Forrest Gump shrimp boat level success. 😎

0 · Reply

JohnCardin Oct. 10 at 8:08 PM

$TNYA China proof!

0 · Reply

BadyBady Oct. 10 at 6:17 PM

0 · Reply

DylanGFM Oct. 10 at 5:49 PM

$UAMY $CRML $TNYA $ONMD $DVLT best swing plays

0 · Reply

mansleeping373 Oct. 10 at 5:26 PM

$TNYA Lol. I slept through the pump this morning. Feeling pretty great overall, even after the pullback. Let's just end this day positive, PLEASE.

0 · Reply

popeyecallings Oct. 10 at 5:08 PM

$TNYA 😏

0 · Reply

wins2love Oct. 10 at 4:48 PM

0 · Reply

ezg43 Oct. 10 at 3:30 PM

$TNYA (love emoji) lFG

0 · Reply

mattr7070 Oct. 10 at 3:17 PM

$TNYA she’s fighting

0 · Reply

Stockley_Bulbousberries Oct. 10 at 3:08 PM

$TNYA

0 · Reply

KeenAshford93 Oct. 10 at 2:58 PM

$TNYA These motherfuckerz brining it down fast

1 · Reply

Psypsyd Oct. 10 at 2:53 PM

$TNYA

0 · Reply

ursus_horribilis Oct. 10 at 2:53 PM

$TNYA Since today is Friday, and the conference is on Tuesday, traders appear to be unwinding positions ahead of the event rather than waiting until Monday — suggesting early profit-taking and reduced short-term confidence.

1 · Reply

LJB411 Oct. 10 at 2:33 PM

$TNYA Strong buyer here. Finally decided to create a TikTok to start sharing more publicly my calls after my recent good fortune. I'll still post on here. https://www.tiktok.com/t/ZTMAVmdqX/

0 · Reply

BadyBady Oct. 10 at 2:32 PM

$CUBE $IOBT $MRKR $TNYA Told You😎

0 · Reply

ursus_horribilis Oct. 10 at 2:24 PM

$TNYA has been climbing ahead of the Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025 — but that momentum won’t last. With all programs still early-stage — Phase 1b/2 (MyPEAK-1), Phase 1b (RIDGE-1), and preclinical — there’s no real catalyst to sustain the rally. Once the event hype fades, a sharp pullback is imminent.

0 · Reply

King_of_Bio Oct. 10 at 2:18 PM

$TNYA I said it once...but it needs to be said again THE TURN AROUND HERE IS INSANE !!!

1 · Reply

USA_toinfinityandbeyond Oct. 10 at 2:04 PM

$NKLR $TNYA $ARAY $PLUG Which one do you think will take off first? I like them all, but I'm betting NKLR can double or triple pretty soon.

1 · Reply

ezg43 Oct. 10 at 1:45 PM

$SGMO $TNYA Just tryn ta help (Wink Emoji)

0 · Reply

JohnCardin Oct. 10 at 1:43 PM

$TNYA Super Bullish!

0 · Reply

Market Cap	342.25M
Revenue (ttm)	0.00
Net Income (ttm)	-111.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	10,064,601
Avg Vol	3,874,506
Day's Range	N/A - N/A
Shares Out	162.98M
Stochastic %K	71%
Beta	3.15
Analysts	Strong Sell
Price Target	$10.14